



Daily *Derivatives*

12 May, 2026

DERIVATIVES

Key Indices

Index	Close	Changes (%)
NIFTY	23815.85	-1.49
SENSEX	76015.28	-1.70
BANKNIFTY	54439.90	-1.57
INDIA VIX	18.55	10.17

Market Outlook

The NIFTY 50 continued to remain under selling pressure amid the weaker global cues, declining nearly one and half percent and settled close to its critical support zone. From a technical perspective, a decisive break down below the current support level could extend the decline towards the 23,500 mark. However, if the index manages to hold this zone, the 24,000 level is likely to act as an immediate hurdle, as fresh call writing has emerged around this strike. Overall, market sentiment continues to reflect a cautious undertone, and the index is expected to trade with a sideways to negative bias in the upcoming sessions due to rise in the crude oil prices.



**TRADE IDEA OF THE DAY -
SUNPHARMA CALL SPREAD**

**BUY 26 MAY 1860 CALL
SELL 26 MAY 1940 CALL**

Entry Range	20 – 24
Target Range	56
Stop Loss	10



Rationale

- On the daily chart SUNPHARMA has witnessed a strong bullish breakout above the 1850 mark, indicating renewed buying momentum after a prolonged consolidation phase. Sustained trading above this level may trigger further upside traction in the near term.
- From the technical prospect, prices are comfortably trading above its 20-DEMA and 50-DEMA, reflecting a positive trend structure. The short-term moving averages are also supporting the ongoing upward momentum.
- Momentum indicators remain constructive, as RSI is gradually moving towards the bullish zone near 60, while MACD has generated a positive crossover with rising histogram bars, confirming strengthening price momentum.
- For the near term one can adopt a buy-on-dip strategy near the 1840-1850 support zone to build Bull Call strategy with the upside resistance of 1940 and downside support near the 1800 zone.


NIFTY

Nifty	23860.00
OI (In Lots)	278553
CHANGE IN OI (%)	6.01
PRICE CHANGE (%)	-1.55


BANKNIFTY

Nifty	54572.80
OI (In Lots)	79023
CHANGE IN OI (%)	2.34
PRICE CHANGE (%)	-1.70


NIFTY OI




BANKNIFTY OI



FII's Activity Index Futures



FII's Long Short Ratio



Long Buildup

Name	LTP	% Change	OI (Lots)	% OI Change
TATACONSUM	1269.2	7.58	19873	17.77
BIOCON	394.5	3.26	12671	8.11
BANKINDIA	144.84	3.39	12994	7.16
HYUNDAI	1900.3	5.79	36067	6.93

Short Buildup

Name	LTP	% Change	OI (Lots)	% OI Change
DALBHARAT	1791	-2.43	10348	18.20
KALYANKJIL	385.55	-9.41	31865	16.53
SBIN	960	-4.34	128422	12.45
BHARTIARTL	1772.5	-3.79	118601	9.89

Breakout Stocks (1 Month High)

Name	LTP	% Change	22 DAY HIGH
IDEA	12.25	8.41	11.49
TATACONSUM	1269.7	7.62	1196.3
LAURUSLABS	1268.8	2.91	1241.8
MCX	3198.9	2.91	3142.3

Breakdown Stocks (1 Month Low)

Name	LTP	% Change	22 DAY LOW
KALYANKJIL	385.65	-9.39	401.55
SBIN	959.6	-4.38	996
DALBHARAT	1780.8	-2.99	1822
BHARTIARTL	1768.1	-4.03	1783.6

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	LTP*	S1*	S2*
ADANIANT	2523	2545	2500.2	2469	2437
ADANIPTS	1791	1815	1767.3	1738	1710
APOLLOHOSP	8143	8204	8082	8022	7961
ASIANPAINT	2598	2629	2566.1	2545	2523
AXISBANK	1286	1300	1272.3	1255	1238
BAJAJ-AUTO	10660	10725	10595.5	10521	10447
BAJAJFINSV	1810	1826	1794.2	1782	1770
BAJFINANCE	950	964	936.05	928	919
BEL	437	442	431.95	429	426
BHARTIARTL	1801	1842	1759.8	1737	1715
CIPLA	1337	1368	1304.9	1287	1268
COALINDIA	469	474	464.45	456	448
DRREDDY	1296	1312	1279.9	1268	1257
EICHERMOT	7261	7320	7202.5	7151	7100
ETERNAL	251	257	245.87	243	239
GRASIM	3018	3052	2984.2	2939	2894
HCLTECH	1204	1213	1194.9	1189	1182
HDFCBANK	772	780	763.65	759	754
HDFCLIFE	629	635	622.7	614	605
HINDALCO	1037	1050	1023.5	1016	1009
HINDUNILVR	2330	2352	2307.2	2272	2237
ICICIBANK	1277	1288	1266.4	1254	1241
INDIGO	4396	4492	4299.4	4240	4180
INFY	1185	1194	1177	1170	1164
ITC	308	309	305.85	305	303

*R1 - Resistance 1 | *R2 - Resistance 2 | *LTP – Last Traded Price | *S1 - Support 1 | *S2 - Support 2

NIFTY 50 - STOCKS KEY LEVELS

SYMBOL	R1*	R2*	LTP*	S1*	S2*
JIOFIN	245	249	240.33	238	236
JSWSTEEL	1277	1291	1262.6	1253	1244
KOTAKBANK	387	392	381.05	375	369
LT	3967	3994	3940.2	3900	3859
M&M	3284	3322	3245.9	3216	3186
MARUTI	13683	13883	13483	13257	13031
MAXHEALTH	1052	1066	1037.95	1014	990
NESTLEIND	1497	1511	1481.9	1469	1456
NTPC	402	410	392.95	388	382
ONGC	283	284	281	279	276
POWERGRID	313	316	310.9	309	308
RELIANCE	1417	1445	1388.2	1371	1353
SBILIFE	1898	1912	1884.4	1867	1850
SBIN	997	1020	973.6	961	948
SHRIRAMFIN	988	999	975.95	967	959
SUNPHARMA	1897	1922	1872.7	1837	1800
TATACONSUM	1300	1330	1271	1221	1171
TATASTEEL	214	216	212.08	211	209
TCS	2415	2437	2392.9	2371	2349
TECHM	1471	1485	1457.4	1448	1438
TITAN	4340	4474	4205.6	4111	4016
TMPV	350	355	346	343	341
TRENT	4229	4277	4181.1	4143	4105
ULTRACEMCO	11944	12023	11866	11780	11695
WIPRO	198	199	196.68	196	195

*R1 - Resistance 1 | *R2 - Resistance 2 | *LTP – Last Traded Price | *S1 - Support 1 | *S2 - Support 2

Our Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Rajan Gupta	rajan.gupta1@religare.com
Vivek Chandra	vivek.chandra@religare.com
Himanshu Gupta	himanshu.gupta1@religare.com

Before you use this research report, please ensure to go through the disclosure interalia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

S.No.	Statement	Answer	
		Tick Appropriate	
		Yes	No
1.	I/we or any of my/our relative has any financial interest in the subject company? (If answer is yes, nature of interest is given below this table)		No
2.	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of the research report or date of the public appearance?		No
3.	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of the public appearance?		
4.	I/we have received any compensation from the subject company in the past twelve months?		No
5.	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
6.	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
7.	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
8.	I/we have served as an officer, director or employee of the subject company?		No
9.	I/we have been engaged in market making activity for the subject company?		No

2014 is/are as under:

Statements of ownership and material conflicts of interest, compensation – Research Analyst (RA)

Nature of Interest [If answer to f (a) above conflicts is Yes

.....]

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to

Copyright: This document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.